1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow rigosertib: new trials by email Literature Review of rigosertib trials Research Report on rigosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC) - Myelodysplastic Syndrome, MDS | Phase 3 | Terminated | Traws Pharma, Inc. | 372 | 2015-12-02 | 2022-09-26 |
| Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts ON 01910.Na - Myelodysplastic Syndromes, MDS | Phase 3 | Completed | Traws Pharma, Inc. | 299 | 2010-11-01 | 2020-06-30 |
Anemia, Refractory, with Excess of Blasts (2) · Myelodysplastic Syndromes (2) · Leukemia, Myelomonocytic, Chronic (1)
Belgium (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · United States (2) · Australia (1) · Austria (1) · Canada (1) · Croatia (1) · Czechia (1) · Estonia (1) · Hungary (1) · India (1) · Ireland (1)
2015 (1)